220 related articles for article (PubMed ID: 32351136)
1. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
2. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
3. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
4. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.
Patel VA; McCullum C; Sparks AD; Schmults CD; Arron ST; Jambusaria-Pahlajani A
Cancer Med; 2022 Jan; 11(1):94-103. PubMed ID: 34796670
[TBL] [Abstract][Full Text] [Related]
6. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
8. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the American Joint Committee on Cancer Seventh Edition and Brigham and Women's Hospital Cutaneous Squamous Cell Carcinoma Tumor Staging in Immunosuppressed Patients.
Gonzalez JL; Cunningham K; Silverman R; Madan E; Nguyen BM
Dermatol Surg; 2017 Jun; 43(6):784-791. PubMed ID: 28079640
[TBL] [Abstract][Full Text] [Related]
11. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
[TBL] [Abstract][Full Text] [Related]
12. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.
Karia PS; Jambusaria-Pahlajani A; Harrington DP; Murphy GF; Qureshi AA; Schmults CD
J Clin Oncol; 2014 Feb; 32(4):327-34. PubMed ID: 24366933
[TBL] [Abstract][Full Text] [Related]
14. Stratification of Poor Outcomes for Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients Using the American Joint Committee on Cancer Eighth Edition and Brigham and Women's Hospital Staging Systems.
Blechman AB; Carucci JA; Stevenson ML
Dermatol Surg; 2019 Sep; 45(9):1117-1124. PubMed ID: 30640779
[TBL] [Abstract][Full Text] [Related]
15. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.
Cañueto J; Burguillo J; Moyano-Bueno D; Viñolas-Cuadros A; Conde-Ferreirós A; Corchete-Sánchez LA; Pérez-Losada J; Román-Curto C
J Am Acad Dermatol; 2019 Jan; 80(1):106-113.e2. PubMed ID: 30003984
[TBL] [Abstract][Full Text] [Related]
16. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
[TBL] [Abstract][Full Text] [Related]
17. Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management.
Arron ST; Blalock TW; Guenther JM; Hyams DM; Ibrahim SF; Koyfman SA; Wysong A
J Drugs Dermatol; 2021 Jun; 20(6):5s-s11. PubMed ID: 34076385
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Al-Rohil RN; Tarasen AJ; Carlson JA; Wang K; Johnson A; Yelensky R; Lipson D; Elvin JA; Vergilio JA; Ali SM; Suh J; Miller VA; Stephens PJ; Ganesan P; Janku F; Karp DD; Subbiah V; Mihm MC; Ross JS
Cancer; 2016 Jan; 122(2):249-57. PubMed ID: 26479420
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Burton KA; Ashack KA; Khachemoune A
Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Based on the AJCC-8 and Brigham and Women's Hospital Staging Criteria.
Tejera-Vaquerizo A; Cañueto J; Llombart B; Martorell-Calatayud A; Sanmartín O
Dermatol Surg; 2020 Jul; 46(7):857-862. PubMed ID: 31567487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
